https://doi.org/10.4081/monaldi.2024.3128

Impact of the COVID-19 pandemic on the clinical features of patients with chronic obstructive pulmonary disease: an observational cross-sectional study

Early Access
Submitted: July 8, 2024
Accepted: September 24, 2024
Published: November 20, 2024
Chronic obstructive pulmonary disease, coronavirus infection, hospitalization, respiratory tract, comorbidities
Abstract Views: 0
PDF_EARLY VIEW: 0
SUPPLEMENTARY MATERIAL: 0
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Gaukhar Kurmanova
Department of Clinical Subjects, Al-Farabi Kazakh National University, Almaty, Kazakhstan.
Almas Zhanaev
Department of Pulmonology, City Clinical Hospital No. 1, Almaty, Kazakhstan.
Akzharkyn Kaldybek
Department of Pulmonology, City Clinical Hospital No. 1, Almaty, Kazakhstan.
Balkiya Abdrakhmanova
Department of General Biology and Genomics, L.N. Gumilyov Eurasian National University, Astana, Kazakhstan.
Almira Akparova
akparovaa53@gmail.com
https://orcid.org/0009-0005-0123-8154
Department of Clinical Subjects, Al-Farabi Kazakh National University, Almaty, Kazakhstan.

The presence of chronic obstructive pulmonary disease (COPD) and COVID-19 infection is a detrimental combination for patients and can cause negative clinical consequences. The investigation aimed to compare sociodemographic and clinical parameters of COPD individuals hospitalized for exacerbations before and at the end of the COVID-19 pandemic. An observational cross-sectional study including 222 patients with COPD was conducted in two stages: a survey and assessment of clinical and laboratory data of patients hospitalized from September 2022 to March 2023 (n=98) and processing of the medical histories of patients with COPD who received hospital treatment in 2017 and 2018 (n=124). A comparative analysis of patients who received inpatient treatment for COPD showed that the frequency of patients with Global Initiative for Chronic Obstructive Lung Disease (GOLD) I was half as high after the COVID-19 pandemic, whereas the individuals with GOLD IV were more frequent during the same period (p<0.05). Multiple regression analysis proved the effects of smoking status and previous COVID-19 infection on the health status of patients with COPD according to COPD Assessment Test data (p<0.05). There was an increase in the frequency of comorbid pathologies in the post-COVID period: hypertension, coronary heart disease, gastrointestinal diseases, anemia (p<0.05), and other diseases. This study highlights the significant influence of the COVID-19 infection on people with COPD, which manifested as impaired lung function and an increased incidence of comorbidities.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
Adeloye D, Song P, Zhu Y, et al. Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis. Lancet Resp Med 2022;10:447-58.
WHO. Chronic obstructive pulmonary disease (COPD). 2023. Available from: https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd).
Safiri S, Carson-Chahhoud K, Noori M, et al. Burden of chronic obstructive pulmonary disease and its attributable risk factors in 204 countries and territories, 1990-2019: results from the global burden of disease study 2019. BMJ 2022;378:e069679.
Gulis G, Aringazina A, Sangilbayeva Z, et al. Population health status of the Republic of Kazakhstan: Trends and implications for public health policy. Int J Env Res Publ Health 2021;18:12235.
Agustí A, Hogg JC. Update on the pathogenesis of chronic obstructive pulmonary disease. New Eng J Med 2019;381:1248-56.
Kochnieva O, Kotsar O. The role of microbial biofilms in the development of respiratory system complications in patients with COVID-19: a literature review. Bull Biol Res 2023;5:40-6.
Anzueto A. Impact of exacerbations on COPD. Eur Resp Rev 2010;19:113-8.
Oliynyk OV, Rorat M, Solyarik SO, et al. Impact of alteplase on mortality in critically ill patients with COVID-19 and pulmonary embolism. Virus 2023;15:1513.
Bouquet J, Tabor DE, Silver JS, et al. Microbial burden and viral exacerbations in a longitudinal multicenter COPD cohort. Resp Res 2020;21:77.
Hewitt R, Farne H, Ritchie A, et al. The role of viral infections in exacerbations of chronic obstructive pulmonary disease and asthma. Therap Adv Resp Dis 2016;10:158-74.
Ning Q, Wu D, Wang X, et al. The mechanism underlying extrapulmonary complications of the coronavirus disease 2019 and its therapeutic implication. Sign Transduct Targ Therap 2022;7:57.
Quintero DR, Collazos NE, García AM, et al. Effectiveness of respiratory muscle training in pulmonary rehabilitation programs in patients with Sarcoidosis. A scoping review. Gac Med Carac 2023;131:132-41.
Fließer E, Birnhuber A, Marsh LM, et al. Dysbalance of ACE2 levels – a possible cause for severe COVID-19 outcome in COPD. J Pathol Clin Res 2021;7:446-58.
Singh D, Mathioudakis AG, Higham A. Chronic obstructive pulmonary disease and COVID-19: Interrelationships. Curr Opin Pulm Med 2022;28:76-83.
Dmytriiev D, Dobrovanov O. Post-COVID pain syndrome. Anaesth Pain Intens Care 2021;25:505-12.
Diao B, Wang C, Tan Y, et al. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Front Immun 2020;11:827.
Alqahtani JS, Oyelade T, Aldhahir AM, et al. Prevalence, severity and mortality associated with COPD and smoking in patients with COVID-19: a rapid systematic review and meta-analysis. PLoS One 2020;15:e0233147.
Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. New Eng J Med 2020;382:1708-20.
Kalyanaraman Marcello R, Dolle J, Grami S, et al. Characteristics and outcomes of COVID-19 patients in New York City’s public hospital system. PLoS One 2020;15:e0243027.
Stridsman C, Vanfleteren L, Konradsen JR, et al. Predictors of severe COVID-19 in a registry-based Swedish cohort of patients with chronic obstructive pulmonary disease (COPD). Eur Respir J 2021;58:2101920.
Lutter JI, Jörres RA, Welte T, et al. Impact of education on COPD severity and all-cause mortality in lifetime never-smokers and longtime ex-smokers: results of the COSYCONET cohort. Int J Chron Obstruct Pulmon Dis 2020;15:2787-98.
Meza D, Khuder B, Bailey JI, et al. Mortality from COVID-19 in patients with COPD: a US study in the N3C Data Enclave. Int J Chron Obstr Pulmon Dis 2021;16:2323-6.
Huang BZ, Chen Z, Sidell MA, et al. Asthma disease status, COPD, and COVID-19 severity in a large multiethnic population. J Allerg Clin Immun Pract 2021;9:3621-8.e2.
Gunawan VA, Triyono EA. COVID-19, a self-limiting disease – a case report of a severe COVID-19 pneumonia patient with multiple comorbidities successfully treated without antivirals. Gac Med Carac 2024;132:182-6.
Parisi GF, Indolfi C, Decimo F, et al. COVID-19 Pneumonia in children: from etiology to management. Front Pediat 2020;8:616622.
McIntosh K. COVID-19: epidemiology, virology, and prevention. 2024. Available from: https://www.uptodate.com/contents/covid-19-epidemiology-virology-and-prevention#H4014462337.
Stringhini S, Wisniak A, Piumatti G, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet 2020;396:313-9.
Havers FP, Reed C, Lim T, et al. Seroprevalence of antibodies to SARS-CoV-2 in 10 sites in the United States, March23-May 12, 2020. JAMA Intern Med 2020;180:1576-86.
Miravitlles M, Worth H, Soler Cataluna JJ, et al. Observational study to characterise 24-hour COPD symptoms and their relationship with patient-reported outcomes: results from the ASSESS study. Resp Res 2014;15:122.
Miravitlles M, Ribera A. Understanding the impact of symptoms on the burden of COPD. Resp Res 2017;18:67.
Müllerova H, Maselli DG, Locantore N, et al. Hospitalized exacerbations of COPD: Risk factors and outcomes in the ECLIPSE cohort. Chest 2015;147:999-1007.
Alfageme I, Reyes N, Merino M, et al. The effect of airflow limitation on the cause of death in patients with COPD. Chron Resp Dis 2010;7:135-45.
Yessentayeva SY, Makarov VA, Kalmatayeva ZA, et al. Molecular genetic tests in survival factors in patients with NSCLC in the clinical practice of Kazakhstan. Med J Islam Rep Iran 2021;35:133.
Song Q, Zhao YY, Zeng YQ, et al. The characteristics of airflow limitation and future exacerbations in different GOLD groups of COPD patients. Int J Chron Obstr Pulmon Dis 2021;16:1401-12.
Vestbo J, Edwards LD, Scanlon PD, et al. Changes in forced expiratory volume in 1 second over time in COPD. New Eng J Med 2011;365:1184-92.
Xiong H, Huang Q, Shuai T, et al. Assessment of comorbidities and prognosis in patients with COPD diagnosed with the fixed ratio and the lower limit of normal: a systematic review and meta-analysis. Resp Res 2020;21:189.
Wytrychiewicz K, Pankowski D, Janowski K, et al. Smoking status, body mass index, health-related quality of life, and acceptance of life with illness in stable outpatients with COPD. Front Psych 2019;10:1526.
Wang K, Gheblawi M, Oudit GY. Angiotensin converting enzyme 2: a double-edged sword. Circulation 2020;142:426-8.
Tadic M, Cuspidi C, Grassi G, et al. COVID‐19 and arterial hypertension: hypothesis or evidence? J Clin Hypert 2020;22:1120-6.
Liu Y, Yang Y, Zhang C, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci 2020;63:364-74.
Kamkhen VB, Mamyrbekova SA, Daniyarova AB, et al. Specifics of the mental component of the quality of life of almaty doctors in the context of the COVID-19 pandemic. Phys Activ Health 2022;6:201-7.
Gheblawi M, Wang K, Viveiros A, et al. Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: celebrating the 20th anniversary of the discovery of ACE2. Circul Res 2020;126:1456-74.
Nuritdinov N, Kamilova U. Left ventricular diastolic function in the patients with chronic heart failure. J Amer Coll Cardiol 2018;72:C167.
Esposito L, Cancro FP, Silverio A, et al. COVID-19 and acute coronary syndromes: From pathophysiology to clinical perspectives. Oxidat Med Cellul Longev 2021;2021:4936571.
Canale MP, Menghini R, Martelli E, et al. COVID-19-associated endothelial dysfunction and microvascular injury: from pathophysiology to clinical manifestations. Card Electrophys Clin 2022;14:21-8.
Bartoszewicz M, Czaban SL, Bartoszewicz K, et al. Bacterial bloodstream infection in critically ill patients with COVID-19: a retrospective cohort study. Therap Adv Infect Dis 2023;10:20499361231207178.
SeyedAlinaghi S, Karimi A, Mirzapour P, et al. The relationship between C-reactive protein and levels of various cytokines in patients with COVID-19: a systematic review and correlation analysis. Health Sci Rep 2022;5:e868. Retraction in: Health Sci Rep 2023;6:e1459.
Noels H, Weber C, Koenen RR. Chemokines as therapeutic targets in cardiovascular disease. Arterioscl Thromb Vascul Biol 2019;39:583-92.
Croce K, Libby P. Intertwining of thrombosis and inflammation in atherosclerosis. Curr Opin Hemat 2007;14:55-61.
Kane SV. COVID-19: issues related to gastrointestinal disease in adults. 2023. Available from: https://www.uptodate.com/contents/covid-19-issues-related-to-gastrointestinal-disease-in-adults/print.
Xu E, Xie Y, Al-Aly Z. Long-term gastrointestinal outcomes of COVID-19. Natur Commun 2023;14:983.

Ethics Approval

This research has been accorded with all ethic committee demands of the Al-Farabi Kazakh National University (protocol No. IRB-A403. IRB00010790 Al-Farabi Kazakh National University (IRB#1).

How to Cite

Kurmanova, Gaukhar, Almas Zhanaev, Akzharkyn Kaldybek, Balkiya Abdrakhmanova, and Almira Akparova. 2024. “Impact of the COVID-19 Pandemic on the Clinical Features of Patients With Chronic Obstructive Pulmonary Disease: An Observational Cross-Sectional Study”. Monaldi Archives for Chest Disease, November. https://doi.org/10.4081/monaldi.2024.3128.
Copyright (c) 2024 The Author(s) Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.


Similar Articles

<< < 1 2 3 4 5 6 7 8 9 10 > >> 

You may also start an advanced similarity search for this article.